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 Biodiversity research in megadiverse countries: strategies 
for scientific and technical alliances 
 
 
 
 
1. Introduction 
 
Strengthening scientific and technological capabilities in the countries of origin of genetic resources is 
strategic, particularly to fulfill the commitments of the Convention on Biological Diversity (CBD). 
However, biodiversity research has limitations resulting from the development and implementation of 
the commitments in the CBD itself. In this sense, any restrictions affect both the researchers from the 
countries of origin of genetic resources, as well as the scientists from countries that use biodiversity, 
because the impacts and approaches to their solution are not homogeneous. As a result of such 
situations, scientific and technological capabilities required for the conservation and sustainable use of 
nature in these countries are still pending. 
The megadiverse countries are often characterized by high biodiversity indicators; worrying levels 
of poverty and corruption; scarce scientific and technological research skills, and belonging to a CBD 
category of providers of genetic resources. When compared to countries with advanced technology but 
little biodiversity, the latter are identified as users having an interest in the access to genetic resources. 
Nevertheless, the interest of suppliers also emerges to participate in the benefits derived from the access 
to modern biotechnology, and it becomes necessary to propose a mutual compensation. The 
differentiation of these types of countries was implemented through the CBD on the obligations of the 
supplier countries (Art. 15, 2) and the obligations of the user countries (Art. 15, 7 and 16), establishing a 
distinction that is reflected in the background of international negotiations and regimes on access to 
genetic resources and biological material (Martínez and Biber-Klemm 2010; Biber-Klemm et al. 2010). 
In accordance with the aforementioned description, the policies of international organizations 
prioritize the implementation of biodiversity inventories in supplier countries with the purpose of better 
exploiting its potential use in the industry. Thus, governments, businesses and individuals in user 
countries led research and bioprospecting activities which in some cases included the patenting of 
research results and genetic resources, but without agreeing on a fair and equitable sharing of benefits 
with the countries of origin as envisaged by the CBD. In turn, the countries of origin of genetic resources 
focused on designing schemes and defensive measures in order to avoid misappropriation and protect 
their associated traditional knowledge. The objective in itself is to regulate access and ensure the sharing 
of benefits arising from their use. 
 
 
 
 
Nemogá-Soto G.R.; Rojas Díaz, D.A. and Lizarazo Cortés, O.A. 2014 Biodiversity research in megadiverse 
countries: strategies for scientific and technical alliances. In: Rios, M. y Mora, A. (Eds.), Access to Genetic 
Resources in Latin America and the Caribbean: Research, Commercialization and Indigenous worldview. IUCN-
UNEP/GEF-ABS-LAC. Quito, Ecuador.  Pp. 13-42. 
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Access regimes generate unexpected effects on national research systems, because they do not 
encourage research and innovation (Martinez and Biber-Klemm 2010). At the same time, they have lacked 
an effective international regime that works beyond national jurisdiction until now. Additionally, the 
technical and scientific developments in areas such as genomics, bioinformatics and synthetic biology, as 
well as the standards and dynamics of international research, have made some of the provisions 
established to control flow, transfer and utilization of genetic resources and its associated information 
obsolete. 
In this context, the present study outlines the difficulties that scientific research faces following 
the negotiations which led to the CBD and the definitions on the subject of access to genetic 
resources. Thus, it tries both to establish criteria to differentiate scientific and commercial research, 
such as finding regulations designed to promote and support scientific research in order to strengthen 
scientific and technological capabilities in the countries of origin of biodiversity. Also, the scope of Art. 
8 (a) and its relationship with Art. 23 of the Nagoya Protocol is analyzed to understand scientific 
research as a part of the innovation value chain and its development, as this is the basis for a 
differential treatment. After this analysis, the prevailing standards and practices in scientific research 
are contrasted with relation to the budgets of access regimes that seek to control and monitor the use 
and exploitation of genetic resources and associated knowledge. 
Being able to show the unintended effects of access regimes is achieved by describing two cases 
of scientific research in countries of resources. The first is an exploration project conducted by an 
international institution in a nature reserve in Ecuador, entitled "Global Ocean Sampling Expedition, 
Galapagos National Park: collection activities and implementation of legislation." The second is a 
project developed by a national institute in Colombia, entitled "Research on a microorganism of the 
genus Lactococcus sp., Institute of Biotechnology, National University of Colombia." 
Both case studies document the details on what happened in Colombia and Ecuador, becoming a 
reference for analyzing the scope and potential of the provisions included in the Nagoya Protocol on 
facilitating access to scientific research. The characteristic elements of two solutions to facilitate both 
access to biodiversity as well as scientific research, revolve around the problems illustrated.  One of the 
solutions is led by researchers from a user country, while the other was elaborated by a country of origin 
of genetic resources. 
The results suggest the need to overcome the dominant characterization which identifies 
megadiverse countries as suppliers, since this emphasis has implications for international negotiations and 
national decisions on biological research and biotechnology development. Thus, the final considerations 
will highlight what are the main problems faced by exploration of biological and genetic diversity, 
emphasizing the need and opportunity for the countries of origin of resources to become stronger at a 
scientific and technological level. 
In summary, the case studies indicate that regulations in the regimes on access to genetic 
resources must be aligned to the objectives of the CBD in megadiverse countries. This is why we must 
strengthen endogenous scientific-technological capacities applied to research on biodiversity and its 
sustainable use to generate profits. Achieving this is crucial, but requires a serious commitment from 
user countries with advanced technology to build programs and cooperation mechanisms, all of which 
will aim at removing existing asymmetries with their peers in the supplier countries. 
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2. Scientific scenario and the subject of access to biodiversity 
 
Researchers who promote a facilitated access to scientific research from countries considered users of 
biodiversity encounter a definition of genetic resources in Art. 2 of the CBD that is very general (Martinez 
and Biber-Klemm 2010). In particular, it is reported that the term includes any biological material with 
microbial or different functional units of heredity, deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), 
whether from plant, animal, microbial or other origin, but all having real or potential value. From this point 
of view, all research using samples having functional units of heredity would be within the framework of 
the access regimes (Martinez and Biber-Klemm 2010). 
In this scenario concerning access, the perspective of researchers conducting scientific research 
on biodiversity in megadiverse countries is controversial, because they question countries of origin for 
extending their rights to the biochemical products –as is the case of Costa Rica– or other derivatives 
such as synthetic molecules –like in the case of the Andean Community (CAN). Similarly, during a 
meeting in Germany in 2008, a group of research institutions expressed concern about the broad 
interpretation of the terms “utilization of genetic resources” under the third objective of the CBD. This 
precedent led to the Nagoya Protocol to define its meaning in Art. 2 (c) as “conducting research and 
development on genetic resources and/or on the biochemical composition of genetic resources, 
including their application through biotechnology as defined in Art. 2 of the CBD." 
For countries rich in biodiversity, the legal definitions of the object pose access difficulties from 
the point of view of control, monitoring and resource monitoring given technological advances and 
research practices. The proposal of regulations for Decision 391 of 1996, developed at the National 
University of Colombia (Nemogá-Soto 2010), highlights the need to formulate a definition that 
reflects technological advances. It also refers to genetic information when defining genetic resources 
and seeks a comprehensive regulation for biological organisms, genetic material, genetic information 
and byproducts. The elaborated definition considers new technological realities and identifies 
biogenetic resources as: "any biotic component of a biotic system from the molecular level to the 
biome and its genetic information, of real or potential value or utility, which is contained in samples of 
a full or partial viral , microbial , fungal, plant or animal specimen in the form of extracts, molecules or 
substances produced by its metabolism, and which have been obtained naturally or synthetically  from 
dead or living organisms, whether they are under in situ or ex situ conditions" (Nemogá-Soto 2010). In 
itself, this approach is based on Decision 345 of 1993 which foresaw the establishment of a common 
regime on access to biogenetic resources in the countries of the CA. 
The above definition recognizes a technological fact that is omitted in access regimes and can 
make them dysfunctional, since the definition of genetic resources in the CBD is limited when facing 
the technological versatility that allows access to the encoded information in DNA and other derived 
molecular structures, since once it has been accessed it is used for commercial purposes. It is worth 
noting that some definitions of genetic resources remain anchored in outdated genetics _which disregard 
the development of genomics, bioinformatics and synthetic biology; but it must be said that Pastor and 
Ruiz (2009) presented a pioneering study on this issue in the region which the Nagoya Protocol analyzed 
in the context of its negotiations, but with little practical results. 
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The concern about the definition lies in the implications for different stakeholders. In the case of 
the countries of origin of genetic resources, there are implications regarding the exercise of rights and 
the achievement of objectives such as a fair and equitable benefit sharing arising from the utilization 
of resources and products. In the case of users interested in access for research or commercial 
developments, the implications are manifested in terms of procedures and authorizations required for 
its use, because they must avoid legal disputes and ensure legal guarantees over the eventual 
commercialization of resources or research results. In this respect, conventional definitions resulting 
from negotiation –not from scientific validation– are used. For instance, although one may question 
the scientific basis of the distinction between biological and genetic resources, several regulations 
contemplate and establish parallels and different regimes for access (Nemogá -Soto 2008). 
It is the economic and technological context of the use of resources and research results that 
turns the definition into a subject to negotiation. This is why the definitions of the CBD are the result 
of arduous negotiations that include concepts influenced by an economic perspective. For example, 
the concept of genetic resources refers to the actual or potential value; but in practice, recombinant 
DNA or genetic material has potential uses in commercial applications because of the applied 
biotechnology, regardless of what biological organism it is. Within this economic and technological 
scenario, it becomes difficult to differentiate between commercial and non-commercial scientific 
research because research activities are adding value and information to the genetic material. 
 
 
3. Distinction between commercial and non-commercial research 
 
At present, it is necessary to find a clear distinction between non-commercial scientific research 
and commercial research oriented to product development as criteria for exceptional treatments in 
access to genetic resources; seeing as in the case of bioprospecting and biotechnology linked to the 
development of new biochemical compounds, such differentiation is less clear. The definition of non-
commercial research, given by research institutions in biodiversity during the negotiations of the 
Nagoya Protocol, matches the operative and unapproved text of the Eighth Meeting of the Ad Hoc 
Open-ended Working Group on Access and Benefit Sharing (CBD 2009), stating that the purpose is to 
increase public knowledge without intending to establish restrictions or property rights (CBD 2009). 
Operationally, the definition emphasizes a subjective element and focuses on the control or 
dissemination of research results. 
Leary and colleagues (2009) proposed to examine the scientific and commercial interest in research on 
marine genetic resources based on a review of literature and patent databases. This analysis covers 
bioprospecting activities, including everything, from sampling conducted by academic institutions with public 
funds to developing and marketing products for the biotechnology industry. The team found that during 
phases of isolation, characterization and culture of microorganisms, laboratories -regardless of whether 
they are financed by public or private resources- participate. However, the results of scientific research –
called basic by some– made it possible to establish the Verenium Corporation which markets FuelzymeTM, 
an enzyme that comes from marine genetic resources collected from public funds (Leary et al.2009)
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At the same time, Lopez Cabrera Medaglia and Silva (2008) highlight the difficulty of separating 
basic from commercial research which stands out as a persistent problem in the various access regimes, 
and indicate: "A more general question is whether scientific and commercial research must be 
differentiated. While this is desirable to encourage scientific research, the distinction is not always 
obvious. Often, scientific research leads to subsequent marketing "(Dross and Wolff 2005, quoted in 
Lopez Cabrera Medaglia and Silva 2008). 
The scenario of funding for biotechnology research has changed leading to greater private 
capital investment particularly in countries with developed technology, making it difficult to 
distinguish the sources of funding. The growing on private capital of genetic research common in this 
day and age, dependence changes the dynamics and standards of the dissemination of scientific 
results because and confidentiality and restrictions arising from the application of intellectual property 
regimes are becoming more widespread. Several factors influencing this change are: the alliances of 
research institutions with the industry; the participation in trade initiatives; the use of patents and plant 
breeders' rights as indicators of academic productivity and institutional prestige; the institutional promotion of 
biotrade programs and the viability of business initiatives stemming from research results. These factors, as a 
whole, have the effect of restricting the free exchange of results and materials among researchers and 
institutions; reaching effect where the institutional and legal context in which it the activities of use and 
exchange of genetic materials, information and access to results unfold, is increasingly characterized by a 
tension between an open dissemination system and a proprietary system for biological material and 
associated information (Welch, Shin y Long 2012). 
An owner is the system that supports the sovereign rights of countries of origin in the CBD and 
in turn implies responsibility for the conservation of biodiversity; under this objective, participates in 
the distribution of benefits, and it counters actions of misappropriation of resources and traditional 
knowledge. Thus, the distinction between commercial and non-commercial research is problematic for 
countries of origin, which is why it is necessary to establish differences based on the use of genetic 
resources, but –just like with other distinctions which emphasize subjective aspects– the difference ends 
up being focused on the declared intention at the beginning of the research. For the above reasons, 
López Cabrera Medaglia and Silva (2008) suggest: "Choosing intention as the defining criterion will 
establish a clear and predictable situation for the researchers and the industry receiving biological 
material." Also, you must also consider the difficulty of determining the intention for each sample 
transfer and use of the material once it leaves the country. A subjective test does not provide legal 
certainty for any of the parties involved in the access contract negotiations and execution. 
At present, it is still required to establish essential differences between commercial and non-
commercial research. This is why, when one must distinguish between biological and genetic diversity 
for trade, one opts for listing just basic common features including: 
i. Both los cases require access to genetic resources and associated traditional knowledge. 
ii. Collection and analysis generate information and increase the value of the resources. 
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iii. Research methods are: collection, identification of reference specimens, biochemical analysis and 
genetic sequencing. 
iv. Research centers and universities can do both commercial research and non-commercial 
indistinctively. 
v. The research results are likely to be applied to the conservation and sustainable use of biodiversity. 
vi. The result of the investigation may acquire commercial value and become a private appropriation 
through intellectual property rights. 
 
The types of commercial and non-commercial research differ when the results are focused on 
obtaining profit, which display distinctive characteristics such as: 
i. Confidentiality and control over research results and information. 
ii. The dissemination of the research is subject to directives on intellectual property, particularly in 
the interest of applying for patents or preserving trade secrets. 
iii. The exclusive property rights over industrial applications and over derived economic benefits. 
iv. The reserved and restricted access and transfer of reference specimens and associated 
information. 
v. The privileged transfer of material and information to business partners. 
vi. Agreements with commercial or industrial partners for research on specific uses or scaling of 
production. 
 
In summary, all the above elements are only observable during the research process or after 
results are obtained, but they do no contribute to differentiating their type at the starting point of 
access to genetic resources or derivatives (UNEP/CBD 2008). In other words, these features do not 
provide criteria to distinguish between commercial and non-commercial research stated in access 
requests. 
 
 
4. 4. Facilitated access to scientific research 
 
From their inception, regimes developed in exercise of sovereign rights recognized in the CBD arouse 
concern among researchers, especially regarding possible restrictions on access and exchange of 
genetic resources (Rull and Vegas-Vilarrúbia 2008). In themselves, access regimes focus on ensuring 
benefit sharing arising from the use of genetic resources and on countering situations of illegal 
appropriation and exploitation. This is the reason why some research institutions and researchers 
respect the rights of countries of origin and of indigenous and local communities accepting and 
adopting guidelines for observation.  In the context of international negotiations, the signatories of 
the CBD adopted the Bonn Guidelines at the Conference of the Parties COP 2002, on a voluntary 
basis. Thus, they abide by some international institutions adopting best practice protocols and 
parameters to observe the regulations on access for its researchers (Vale, Alves and Pimm 2008; 
Biber-Klemm et al. 2010). 
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The voluntary scheme and its exceptional adoption appears to be unsatisfactory for 
megadiverse countries, particularly with respect to fair and equitable benefit sharing; so, actions were 
promoted at the World Summit on Sustainable Development in 2002 in order to adopt the decision of 
establishing an international regime on access. Subsequently, negotiations are aimed at ensuring that 
national regulations pertaining to access and benefit sharing, referring to the use of biological 
material, genetic resources and derivatives, are met, thus  encouraging scientific activism in 
international forums (Jinnah y Jungcurt 2009). Welch, Shin and Long (2013) indicate that the 
establishment of an international regime on access in order to make benefit sharing effective has global 
implications, including countries that are not part of the CBD. One of these cases would be the United States of 
America, a country that has yet to ratify the CBD, and whose researchers would be subject to the measures of 
the Nagoya Protocol once it enters into force when they require to collect, exchange and use genetic resources 
in countries who are Parties to the CBD. 
Concerns about restrictions on access regimes are also expressed by researchers from the 
countries of origin of genetic resources, because their ineffectiveness has led to a substantial part of 
their research being illegal due to lack of appropriate access contracts. In some cases the 
environmental authorities have imposed sanctions on researchers and research institutions (MAVDT 
2010), generating an increasing lawlessness in the projects developed by local researchers.  When 
analyzing the asymmetries between countries of origin and user countries in terms of research 
capabilities, funding opportunities and division of labor, it is shown that they vary for researchers 
depending on the context. However, there is consensus on the fact that an access regime with high 
transaction and time costs does make it impossible to establish cooperation agreements and 
international research programs. 
 
 
5. Capacity building in countries country of origin 
 
In response to the concerns of researchers in the international context, Art. 8 (a) of, the Nagoya 
Protocol plans to introduce an exceptional treatment for non-commercial research in the regulations 
on access, stating that: "It will create conditions to promote and encourage research which 
contributes to the conservation and sustainable use of biological diversity, particularly in developing 
countries, including through simplified measures on access for non-commercial research purposes, 
taking into account the need to address a change of intention for such research”. 
In line with the objectives of the CBD, Art. 8 (a) establishes a commitment for all countries party 
to the Convention to constitute conditions that promote research, thus contributing to the 
conservation and sustainable use of biodiversity. However, although the commitment includes all 
countries, the references to developing countries in particular suggest that it is there that scientific 
and technological scenarios should take place. Thus, Art. 8 (a) illustrates the conditions that can 
promote and encourage research, referring to measures on access for non-commercial research 
purposes,  but their establishment is up to the countries with access regimes since in practice it is their 
obligation as the owners of biodiversity. 
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When raising the issue of a differentiated treatment for non-commercial research, the Nagoya 
Protocol anticipates that the intention may change, especially due to the discovery of results with 
commercial potential (CBD 2009). Since this is a subjective aspect, if this intention is not voluntarily 
declared, it is difficult to establish the change in direction. In order to address this issue, the design of 
access regimes and regulations must identify objective indicators of commercial intent to be included 
in the mutually agreed terms (MAT) (UNEP / CBD 2008).  The following are some of this indicators: 
i. The restrictions on the dissemination of research results, for example agreements of reserve or 
confidentiality of results. 
ii. The limitations on the participation of researchers from the supplier country as collaborators or 
coauthors. 
iii. The publication of the results without allowing preliminary access to such results by the authority 
of the supplier country. 
iv. Delays in the public dissemination of the data resulting from the research. 
v. The payment of high fees for access to data, technologies or materials resulting from research. 
vi. The retention of monetary benefits from the sale or transfer of economic benefits, patents, or 
licenses stemming from research findings. 
vii. The transfer of material to commercial partners. 
viii. Contracts with reserved rights to apply for patents or to have control of intellectual property rights 
(IPR). 
ix. Research on commercial application, contracts with a commercial entity or stakeholder, or the 
realization of market research. 
x. Product development or technology testing as part of a broader undisclosed project. 
xi. Forms of contractual restrictions on the dissemination and subsequent use of the results. 
 
In line with the Nagoya Protocol, access regimes and regulations must identify the indicators 
that show the change of Intention in the research. The same situation arises in connection with 
marketing indicators for byproducts, namely non-genetic resources derived from genetic ones and 
which are subject to the fair and equitable benefit sharing (CBD 2008). Here are some examples: 
i. Marketing and market availability or sale to the public. 
ii. Seeking approval for marketing or other authorizations such as product registration. 
iii. Filing for intellectual property protection. 
iv. Identifying a specific use for a byproduct. 
 
Due to its scope in designing policies and making decisions on access regulations, it is pertinent to read 
Art. 8 (a), in conjunction with the provisions of Art. 23 on technology transfer, collaboration and cooperation, 
because it allows you to define actions to strengthen the capacities of countries identified as suppliers. Art. 23 
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of the Nagoya Protocol states that the parties will collaborate and cooperate in technical and scientific 
research, and development as a means to achieve their goals, particularly in developing and insular 
countries to improve their technological and scientific basis. 
The language used in Art. 23 differs from the one used in Art. 8 (a), because the former 
promotes conducting research in the countries of origin of genetic resources, as long as research is 
possible and appropriate when pointing out that the parties seek to promote and advance access to 
technology. The terms used are lax and its wording –incorporated in the Bonn Guidelines– leaves 
voluntary commitment in this area unchanged (Secretariat of the Convention on Biological Diversity 
2002). In other words, Art. 23 does not generate enforceable commitments for countries possessing 
technology and involving their obligation to contribute to strengthen the technological base of 
biodiversity-rich countries. In contrast, Art. 8 (a) incorporates an enforceable obligation is that 
biodiversity-rich countries establish simplified measures on access for research purposes. 
In accordance with Art. 23 of the Nagoya Protocol, Art. 8 (a) also reiterates a concept which 
characterizes international negotiations in which countries rich in biodiversity are considered primarily 
suppliers. This is also assumed by researchers from developed countries when they urge for access to 
genetic resources for research purposes to be facilitated, because in scientific publications they set 
themselves apart from scientists from countries identified as suppliers (Jinnah and Jungcurt, 2009; 
Martínez and Biber, 2010). This difference in perspective is historical and evidences the asymmetries 
between researchers from developed and developing countries in terms of research priorities, division 
of labor and shared authorship of results (Jinnah and Jungcurt, 2009). Art.8 (a) does not go beyond 
this view, since the assumption of this rule pertains to supplier countries with limited scientific 
capabilities and user countries of biodiversity, without the latter acquiring effective commitments to 
strengthen the scientific and technological capabilities of the former (CBD 2009) . 
Decision-makers of public policy decisions and access legislation have an opportunity in this area, 
especially for countries rich in biodiversity to develop, as provided in Art. 8 (a), in a manner that satisfies the 
priority and need to strengthen their capacities. In itself, the strengthening of scientific and technological 
capacities and research on biodiversity in their countries, becomes a requirement for the exercise of the 
sovereign rights of the country (Unimedios, 2009). In carrying out Art. 8 (a), the biodiversity-rich 
countries can establish clear parameters to facilitate access to genetic resources for scientific research, 
taking into account that their participation is a priority in programs and projects, and is not limited to 
being just a supplier of resources or facilitating access to associated traditional knowledge. Therefore, if 
all this adds to the perspective of Art. 6, the situation must be instrumented so that the prior informed 
consent (PIC) and MAT jointly contribute to strengthening national capacities. The two instruments are 
necessary when considering the eventuality of a change of intention in research, the use of third-party 
resources and the forecasts of availability of research results for public access. 
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6. Scientific research and the addition of economic value to biodiversity 
 
Scientific research on biological and genetic diversity can be analyzed in terms of its role in the 
generation of innovation and the creation value. This is why Martinez and Biber-Klemm (2010) see it 
as part of a value chain which adds to the amount resources. The process begins with basic non-
commercial research, followed by scientific and technological development and ending in the 
marketing of products (UNEP / CBD 2008). The scheme for adding value is parallel to the generation 
of innovation, because it starts with the resources and expertise found in local indigenous 
communities, continues with the scientific activities of collection of biological material and associated 
specimen identification and classification of information, and experimentation. Later, it continues 
with the genetic characterization and isolation of its components according to their potential uses, 
and it end with the development and testing of industrial and biotechnological applications, scaling 
and commercialization. In this chain of value addition and innovation, researchers have a key role 
since they participate in every step of the process and generate new results for science. 
The results of the research are published in accordance with the existing compromises with the 
sponsoring entities and, once disseminated, they are integrated to technological development globally. 
The results of the research are published in accordance with the existing compromises with the 
sponsoring entities and, once disseminated, they are integrated to technological development globally. 
At the end of the value chain, if the results of scientific exploration produce marketed products, 
linkages between the place of origin of the resources and the initial knowledge of the communities 
dissolve, and access regimes become less relevant. This also occurs when there is genetic information 
likely to be transferred between researchers or stored in public databases. An example is when the 
concept of a taxonomic conservation research, faces the same requirements and restrictions as 
another that is aimed at marketing resources or results with emphasis on its economic process. The 
point of differentiation continues to be subjectivity of the researchers, since while Martinez and Biber-
Klemm (2010) pointing out that research on conservation and sustainable use is irrelevant and has no 
commercial use,  this argument is sometimes used to justify an exception to the requirements of 
access and facilitate research in taxonomy, ecology, population genetics and evolution, opening the 
possibility for non-commercial research in genetic and pharmacological engineering (Secretariat of 
the Convention on Biological Diversity 2007). This is why, the difficulty with certain research arises when 
resource information would have to be admitted, but not added to the value chain. 
On the levels of political decisions when applying Art. 8 (a) of the Nagoya Protocol, the need to 
define in which areas it is suitable to facilitate access to strengthen capacities in research and 
development should be considered as a key aspect when regulating access to genetic resources. From 
Art. 8 (a) no inflexible orientation or single model for countries to establish access regimes may be 
derived, but it enables them to facilitate and strengthen national research while being aligned with the 
Nagoya Protocol. Thus, endogenous capacities will benefit greatly, making it easier to track all the 
process, from research to innovation through a control of the use of genetic resources, their 
byproducts and associated knowledge. Currently, the assumptions of access regimes are 
overwhelmed by the standards and practices of scientific research. 
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7. Standards of current activities in academia and science 
 
Scientific research is based on standards and practices that go beyond the provisions included by 
countries in their regimes of access to genetic resources, making it difficult to control the transfer and 
use thereof. Research institutes and universities are working with the assumption that research results 
should be published. Very often, scientific journals require the deposit of sequences of genetic 
information during the evaluation process of the articles. This is why, this becomes an unquantifiable 
reservoir of free access to the user community, researchers and businesses. The main databases of 
genetic information (primary) are: GenBank in the United States, coordinated by the National 
Institute of Health; EBI-EMBL in Europe and DDBJ in Japan. The three databases are synchronized 
periodically and have similar information, coordinating some of their activities through the 
“International Nucleotide Sequence Database Collaboration” (INSDC) (http://www.insdc.org/policy. 
html). In addition, the Swiss Prot database excels in the field of protein and there are more than 3000 
secondary databases with genetic information of varying scope. 
Generally the information in the database is publicly accessible and has few restrictions. However, it 
does not mean that all entries are free to be used. On the contrary, some nucleotide and amino acid 
sequences have been set aside for patent applications or patents have already been granted. One example is 
the recent release or version of the European database EBI-EMBL, of entries 266, 255, 715 and 24, 746, 595 
which are sequences for patents or patent applications; out of nucleotides 499, 882, 374, 645 included in the 
version or "release" No. 114, of December 2012, 2.5% –this means 12, 530, 222, 966– correspond to patents 
which have been granted or are pending (EBI-EMBL 2012). Having a lot of information available is useful for 
knowledge, conservation and the sustainable use of biological diversity, but it involves legal and ethical 
challenges. In particular, it involves changes from the traditional conception of scientific endeavors who are 
now welcoming 20 year-old CBD standards, or Decision 391 of 1996, which has existed for 16 years. 
New technologies used in bioscience and biotechnology research are increasingly common in 
developing countries as they use tools such as bioinformatics (Restrepo et al., 2009) to analyze 
information and help solve biological problems, since the cost of these in silico techniques is lower in 
comparison to in vitro or in vivo experiments. For instance,  in the case of Colombia, there are several 
groups of professionals from universities and research centers who have been working since 2007 on 
issues pertaining bioinformatics, genomics and other "omics" (proteomics, transcriptomics and 
metagenomics, etc.) at the GEBIX network, the Colombian Center for Genomics and Bioinformatics of 
Extreme Environment, with the participation of the Universities of Caldas; Cauca; Valle; the National 
University and the Javeriana University, as well as private institutes such as Corpogen and Parquesof 
(Benítez-Páez and Cardenas Brito 2010). Also, during these years the following institutions were 
created: the National Genome Sequencing Center at the University of Antioquia (2010), the 
Colombian Center for Bioinformatics and Computational Biology located in Manizales, Caldas (2010) 
and a master's program in bioinformatics and computational biology at the National University of 
Colombia in Bogota (2012), a pioneer in the country (http://www.agenciadenoticias.unal.edu.co). 
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In this context, some scientific institutions with collections of plant, animal and strain 
germplasm transfer biological material (organisms or parts) as a regular necessary practice for their 
activities, whether it is for backup or specimen for taxonomic analysis by specialists from foreign 
countries. The exchange takes place informally, as it is motivated by close relationships between 
colleagues For instance, a recent study in the United States of plant non-genetic resources, which 
involved more than 400 professionals from federal institutions and universities established that the 
use of a Material Transfer Agreement (MTA) the PIC is low, even among those who have formally 
adopted its use (Welch, Shin Long 2013). 
The requirement of access regimes since the Nagoya Protocol and the increasing adoption of 
regulations pertaining to intellectual property in research institutions, tends to reduce the informality 
of exchanges since it guarantees contractual clauses for the management, transfer and control of the 
material received. Additionally, funders increasingly include the practical use of research results and 
their transfer to the productive sector; for example, when capital is private, both the data and the 
results can become part of the economic assets of the company. Also, the restriction in publication is a 
practice observed by researchers in various fields, particularly if there is investment of private funds, 
tending to add to the limitations that may be imposed by countries of origin of genetic resources 
interested in enforcing their rights of sovereignty. 
Some practices in research processes contradict the assumptions of access regimes, for example 
with provisions contained in Decision 391, which limit it to a certain period of time and then demand 
that the samples be returned or destroyed after the completion of the project. In itself, this 
requirement contradicts the direction of institutions and researchers who invest time and resources in 
the collection and preservation of material whose information can be used scientifically to address new 
questions or train other researchers. 
 
 
8. Status of national research in Colombia 
 
Access regimes elaborated to control the use and misappropriation of genetic resources and associated 
traditional knowledge, are largely misunderstood by national researchers because, from their point of 
view, research on biodiversity does not only satisfy their intellectual curiosity and provide new knowledge, 
but it also implies the free exercise of their right. The regulatory frameworks to enforce the sovereign 
rights of countries of origin of genetic resources and the obligations of the States with their indigenous 
peoples are beyond their quest for knowledge about the biological reality. The assumption of researchers is 
that biodiversity is a natural object of research, with indigenous peoples and local communities 
constituting the social context where the studied natural phenomena occur. Thus, the protocols to be 
followed, the rights of indigenous peoples and local communities, the consents and environmental permits 
to be obtained, are experienced as a complex, costly and illogical social and institutional reality (Chacón y 
Toro 2009). 
In this complex national scientific scenario, being unable to conduct a research proposal, after 
securing financial and institutional support and overcoming a number of difficulties and difficult 
situations because of not getting the contract for access to genetic resources or not conducting the 
prior consultation can be a  frustrating  experience  for  of  a  researcher. In  practice,  funds  raised  for  
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research after investing time and resources, are jeopardized by the impossibility to meet timetables 
due to delays in obtaining environmental permits. 
One consequence is that access regimes may affect the competitiveness of the national 
researcher in terms of knowledge production, for example when the research has to restrict sampling 
methods or sites to be outside the scope of the concepts of genetic resources, byproducts or access. 
The research results may lose specificity and recognition, particularly when molecular techniques 
involving access to genetic resources are excluded. The delay in obtaining access contracts may have 
negative effects on the relevance of the research, as it may lose novelty and relevance in the state of 
the art (Acosta 2009). Other effects on research methods are related to the natural processes that 
take place in certain ecological cycles, where the delay in processing authorizations may prevent 
carrying out the experiments and collections within the prescribed period (Franco 2009). Finally, the 
uncertainty regarding the requirements and the time for procedures make it impossible to make the 
calculations needed to plan scientific activities. 
In the case of Colombia, it has been determined that the procedures associated with the rights 
of indigenous peoples and local communities, such as prior consultation and PIC, are perceived 
negatively by researchers. Nemogá-Soto (2013) presents an analysis of genetic biodiversity research 
and policy in the country (period 1991-2010), evidencing the omission of the rights of indigenous and 
black populations in research processes on their knowledge and genetic resources. Thus, on several 
projects it was decided to exclude Afro-descendant and indigenous territories from the sampling 
areas; so, out of nine cases of access contracts requiring consultation, only three were conducted and 
in the other six, collective territories were eliminated from the study areas (PLEBIO 2012). 
The researcher is unaware of the legal and political parameters that commit the State to 
indigenous peoples and local communities, and so the researcher does not realize that his research 
could affect their cultural integrity or lifestyle. Also, scientists must recognize that these human 
populations are the rightful holders of collective rights over their lands and resources. Some positions 
in academia have even proposed the open rejection of access paperwork and legal procedures, 
ignoring that this guarantees fundamental rights of indigenous peoples (News Agency National 
University 2012). 
The status of research on non- human genetic diversity in Colombia illustrates the unanticipated 
effects on the scientific and technical capacities in countries of origin, especially those who designed 
and approved the access regime set out in Decision 391. One effect is to generate illegality in the 
research, caused by the lack of functionality of access regimes in the Andean countries. Thus, a 
regulatory analysis by the National University of Colombia in 2009 found 565 projects registered in the 
database of ScienTi COLCIENCIAS, all of which had genetic resources without authorization, with the 
study being conducted at the request of the Ministry of Environment, Housing and Territorial 
Development, now known as the Ministry of Environment and Sustainable Development (MADS). The 
same database revealed that 13.7% of the research groups related to biology and related sciences, as 
well as belonging to five National Programs of Science and Technology, have irregular access to 
genetic resources, particularly with respect to biotechnology and agriculture (Nemogá -Soto 2010). 
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During 2012, the first contract for the purpose of industrial application and commercial use for 
the project was signed under the name "Research on a microorganism of the genus Lactococcus sp., 
Institute of Biotechnology, National University of Colombia" (Nemogá-Soto y Rojas Díaz 2013). In 
March 2013, the public database on access to genetic resources of the MADS registered 56 signed 
contracts being awarded for scientific research without commercial interest. However, some cases 
which allow bioprospecting are included within this category. The research of the first 47 contracts 
signed during 2012 is divided into the following topics: taxonomy, evolution and systematics (20), 
population genetics (13) and ecology (1); the remaining 13 have either the interest of applying or 
solving a specific problems, such as the identification of microorganisms that perform particular 
activities; the characterization of substances with a pharmaceutical use and a contribution to human 
medicine. Also, the 47 contracts where implemented by researchers from public and private 
universities, research institutions, public health agencies and environmental authorities. 
With the exception of one contract, all others were awarded to local researchers, whether they 
are individuals and/or institutions, making it difficult to establish whether multinational corporations 
and foreign research institutes use other channels to access Colombian biodiversity, such as access to 
biological resources of border ecosystems. However, contracts of access to genetic resources signed 
by other Andean countries are exceptional. It seems possible that access to genetic resources and 
their byproducts was conducted with permits for scientific research on biodiversity as illustrated by 
the "Global Ocean Sampling Expedition" Case Study in the Galapagos National Park, Ecuador; 
nonetheless, more information (Nemogá- Soto y Lizarazo Cortés 2013) is required. In this sense, it is 
clear that the expectation of Decision 391 in relation with bioprospecting countries with developed 
technology has not been realized since 1996, because in practice, foreign researchers rarely use 
institutional channels of access and there is no substantial evidence of requests filed in the Andean 
region. 
Studies conducted found that the effectiveness of the procedure to obtain the contract for access to 
genetic resources is influenced by actions of both, the applicants and the National Competent Authority 
(NCA) (Nemogá-Soto 2010; Nemogá-Soto and Rojas 2010). On the one hand, the applicant is unaware of 
the requirements of the application and submits incomplete documentation, causing a delay in the delivery 
of the certificate of publication of the administrative order that starts the process, and on the other hand, 
the NCA takes too long to review the application and generate the formal and substantive requirements 
and issue the initial documents and resolutions. 
In Colombia, it is observed that the type of problems in the operation of the access regime 
system varies. For instance, between 2008 and 2009, the NCA signed 18 contracts and reduced the 
duration of the proceedings, but between 2010 and 2012 it signed six contracts (PLEBIO 2012). During 
2012, the MADS was restructured and the group of access to genetic resources was created, which 
meant there was: a better understanding of the procedures, of the explanatory guides regarding the 
process and better communication between applicants and the environmental authority. The case of 
this country demonstrates that it is national institutions and researchers who bear the cost of 
compliance with the access regime; and it is clear that national researchers and institutions contribute 
most of the research with State funding. Similarly, the situation illustrates that neither international 
bioprospectors nor researchers from other countries cooperate substantially with access regimes and 
so, it remains uncertain whether they ever will. In this context, one should consider the need to 
provide facilitated access to national research institutions. 
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The differential treatment is based on Art. 8 (a) of the Nagoya Protocol, and seeks to promote 
and encourage non-commercial research for conservation and sustainable use of biodiversity, as well 
as strengthen the scientific and technological capacities of the countries of origin of the resources. As 
there are precedents for favorable rules for national researchers, López Cabrera Medaglia and Silva 
(2008) cite the Philippines, Brazil, Costa Rica, Malaysia and Australia as regimes with exceptions for 
non-commercial scientific research. To the extent that it pertains to the exercise of sovereign rights on 
access to genetic resources and traditional knowledge and not to intellectual property rights, the 
provisions on national treatment under Art. 3 of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (TRIPS) does not strictly apply. 
Meanwhile, Art. 6 (3, b) of the Nagoya Protocol seeks to provide non arbitrary and fair standards and 
procedures, about access to genetic resources. Similarly, Art. 4 of the Nagoya Protocol reaffirms the principle 
that its validity does not affect the rights and obligations of the parties arising from pre-existing international 
agreements. In designing and establishing legislative, administrative or policy measures, countries rich in 
biodiversity may –in the development of their sovereign rights and national interest considerations– 
encourage the development of non-commercial research and education on ecosystems, creating special 
conditions for national research on genetic resources considered strategically important. 
The exceptional treatment in exercise of the legal faculties which enable access to the countries 
of origin, can be attained through the criteria of PIC and MAT based on a special and strategic interest 
(Greiber et al., 2012). Currently, Brazil has a differential treatment on research related to: the 
evolutionary history of a species or taxonomic group; population genetics; epidemiology studies; DNA 
collection, germplasm tissues and blood; measurement of the concentration of known substances 
that indicate disease; relationship, karyotype or DNA testing to determine a specimen; grown 
commercial varieties of sugarcane and essential oils exploration (Ministério do Meio Ambiente 2006; 
2007 a,b,c). 
 
 
9. Alternatives to promote scientific research 
 
On the basis of the interest of researchers from user countries of biodiversity or megadiverse 
countries, alternatives have been developed for facilitated access which will leverage scientific 
research, as it is a means to achieve the objectives of the CBD. In this sense, two contract proposals 
are examined, which could solve the issue of access to genetic resources. 
 
9.1 Proposed contract template for foreign researchers using biodiversity 
 
Researchers from countries poor in biodiversity are developing a solution for facilitated access to 
biodiversity in situ. In this sense, the Swiss Academy of Natural Sciences (SCNAT) is currently leading the 
elaboration of an agreement template with model clauses, which can be adapted by countries rich in 
biodiversity and researchers without commercial interests. In addition, Biber-Klemm and colleagues (2010) 
suggest that the template can be applied and adapted among providers of genetic resources and 
researchers, particularly for: biodiversity inventories; systematics; ecology; evolution; identification and 
isolation of assets, and genetic compounds. The model is based on a bilateral agreement between providers 
and users, following the premises of Art.15 of the CBD, just contemplating negotiations on access and 
benefit sharing (Biber-Klemm et al., 2010). In this context, the model is applied on a number of conditions 
which include:
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i. The resources are accessed by a researcher under the direction and responsibility of a research 
institution. 
ii. The research is not commercial in nature and its results are available to the public. 
iii. The unexpected results may be susceptible to use in a commercial context. 
iv. The benefits derived are non-monetary as a rule and are generated during the research process. 
v. The genetic resources could be transferred to third parties within the framework of practical 
cooperation between research institutions. 
 
The proposal identifies the risk that even without commercial intent, both the resources as well 
as the information accessed and generated under research premises can be exploited by certain 
initiatives without MAT that cover the distribution of benefits. It is also recognized that the 
researchers’ need for dissemination may conflict with the interest of countries rich in biodiversity to 
control the use and transfer of resources. In particular, researchers are interested in publishing the 
results on time, meeting standards of scientific accuracy and sharing biological material and 
information with colleagues. In this scenario, in issues such as biodiversity inventories and ecological 
studies, where there is a low probability of results of relevance to the commercial sector, it is 
suggested that instead of control over the uses, the countries of origin of the resources could require 
periodic reports on the progress of the research and monitor compliance with the agreements 
reached. 
 
 
9.2 Proposed framework contracts for research institutions and centers 
 
In megadiverse countries, fair and equitable benefit sharing remains a valid and enforceable goal, as 
well as the need to strengthen their endogenous scientific and technological capabilities, proposing 
solutions that facilitate the compliance with the access regime. So in countries that have access 
regimes such as Decision 391, the use of framework agreements (FA) stipulated in its Art. 36, has been 
proposed considering that: "the national competent authority may enter into access contracts with 
recognized universities, research centers and researchers, to support the execution of various projects 
in accordance with the provisions of this Decision and in accordance with the national legislation of 
each member country. " 
The option of Art. 36 is based on the need to provide easier access to academic and scientific 
institutions because they conduct biodiversity research at a country level. In Colombia, for example, 
the adoption of framework agreements with recognized universities and research institutes would 
cover at least 97% of the research on genetic diversity (Nemogá-Soto 2010). One advantage to this 
option is shown in academic and research institutions that become involved as part of the solution, 
because when they identify and organize their thematic lines or areas within their institutions, they 
can ensure that their researchers will observe the access regime. Upon defining the lines of research 
on a framework agreement, institutions may include new projects without starting a new request for 
access to genetic resources. The process in itself generates a contractual relationship, responsibilities 
and obligations between the NCA and the beneficiary institution, who pledges to comply with the 
access regime under pain of administrative and disciplinary sanctions. 
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Some research projects could generate results of commercial interest. In order to exploit or 
license the resources, the beneficiary institution must comply with the requirement of the PIC, 
notifying the NCA and starting the process for establishing a fair and equitable benefit sharing. Some 
criteria for determining the commercial nature of the proposal are to establish relations with the 
private sector in order to: conduct research on the potential use or scaling and testing of products; 
start negotiations for the licensing of research results; determine product offer; obtain a marketing 
registration and finalize arrangements or agreements for the temporary transfer or sale of research 
findings. 
When a properly designed FA is authorized by the NCA using the access regime, it does not give 
up its powers but it manages to build relationships of trust with the research institutions, and these in 
turn acquire clear responsibilities which they must comply with or be sanctioned. In this situation, the 
additional responsibility that the beneficiary institution acquires is compensated by its strengthening, 
because having facilitated access turns it into a reference point for international institutions and 
research centers interested in working with local partners. 
The agreement on access to genetic resources and benefit sharing for academic non-
commercial research from the SCNAT as well as the proposed FA of the National University of 
Colombia, meet the articles and model clauses to be adopted according to the needs of stakeholders 
(Nemogá-Soto 2009; Biber-Klemm et al 2010). The two options are reference points for solutions, 
because they recognize the sovereignty of countries over their natural resources and the legitimacy of 
access regimes. Likewise, these can be strengthened by international instruments such as the Nagoya 
Protocol, enabling partnerships between national and foreign researchers. Equitable participation in 
the design, implementation and use of research results by researchers from the countries of origin, 
become the basis for strengthening their endogenous capacities. Framework agreements regarding 
MAT strengthen trust and transparency with the research objectives, scope and potential uses of 
biodiversity, laying the foundations of respect for the standards set by the states to enforce fair and 
equitable benefit sharing. 
 
 
10. Problems faced by  scientific research in the countries of origin 
 
10.1 Case of the Institute of Biotechnology, National University of Colombia 
 
The Biotechnology Institute of the National University of Colombia (UNC) filed a request for access, 
postulating the project entitled "Isolation and identification of a microorganism of the genus 
Lactococcus sp. as a producer of a natural polymer and exploring its potential industrial and 
commercial applications". This request was filed as scientific research without commercial interest. 
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In this specific case in Colombia, the application process and the research project were 
developed at the same time, advancing to the point of finding results that required a patent 
application and an evaluation of scaling for biopolymer production, with participation of a private 
company. The features of this case reveal several problems under the regime for access to genetic 
resources which are, namely: 
i. The lack of experience and of clear criteria to differentiate between commercial and non-
commercial research. 
ii. The excessive duration of the application process, having taken 11 years to be signed as the first 
commercial contract in the country. 
iii. The requesting institution was sanctioned by environmental authorities for illegal access. 
iv. The patent application was rejected in Colombia, even after being granted other countries. 
v. The patents obtained have not been exploited or licensed. 
 
Some of the milestones in the procedure for obtaining access are: the application was filed in 
August 2001. The administrative order that started the process was issued in December 2003. The 
Resolution of acceptance was issued in March 2010, and the access contract was signed in July 2012. 
Thus, according to Nemogá-Soto and Rojas (2010), the main reasons that influenced the long duration 
of the process could be summarized in the following points: 
i. Ignorance, on the part of both the environmental authority and the applicant, regarding the rules 
for access to genetic resources. 
ii. The mismanagement of the environmental authority regarding the development of requirements, 
technical concepts and administrative acts. 
iii. The incomplete submission of the application and the formulated requirements. 
iv. Changing the request for access to research with commercial purposes during the processing. 
v. The proposed benefit distribution was categorized as unsatisfactory by the NCA. 
vi. The reduced capacity of the NCA to negotiate benefits. 
 
In this case, the UNC was sanctioned for illegal access while conducting scientific research and 
submitting the respective application, but it later benefited from the single contract awarded in the 
country for access to genetic resources for industrial application and commercial gain. The processing 
of this application and its features, allowed the NCA to start building parameters for monetary benefit 
sharing stemming from the access to genetic resources. In 2007 the UNC submitted a proposal to the 
NCA for the distribution of economic benefits during contract negotiations for commercial purposes; 
however, it was not accepted because it did not contain clear monetary figures or proportions. After 
several years of negotiation, the proposal incorporated into the awarded contract awards monetary 
benefits related to industrial and commercial property value. In both situations, it is agreed that the 
MADS will receive 10% of all royalties that the UNC perceives annually. 
The application of the UNC was submitted for the purposes of basic research, but during the 
execution of the research project it went through a transition towards the commercial exploitation of 
the results,  requiring  a  patent  application  and  agreements with a private company for the potential  
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industrial use of the biopolymer. We must recognize that the patent does not guarantee neither the 
exploitation of the invention, nor the licensing or commercialization of research results. Nevertheless, 
the patent was granted in three European countries. Due to the academic and research vocation of the 
UNC and the limited funding for public research institutions, private business investment contributed 
to identify the uses of the biopolymer that might be of interest in the market  and to build the pilot 
plant for production. 
The application process often implies incoherent situations which demonstrate the inexperience 
of the NCA in the effective operation of the access regime, even on the issue of the economic 
sanctions to the UNC in 2010, citing "the access to a genetic resource to isolate and identify a 
microorganism belonging to the genus Lactococcus sp., and get a naturally occurring biopolymer 
through its enzymatic activity, for research purposes "(Art. , Res 1459-1410) without having a contract 
for access to genetic resources. As a basis for imposing the sanction, the NCA considers the patent 
application as proof of the commercial interest of the project. However, between October 2002 and 
April 2003, the pending patent was approved within the framework of the access request, because it 
obtained the export permit for the organism in order to meet the deposit requirement for the patent. 
Another contradictory aspect during the process was the fact that in Resolution 1459 of 
2010, the NCA argued having insufficient information to make an assessment of the application, 
and it was its duty to guarantee the right to a healthy environment and comply with the rules of 
access to genetic resources. In practice, the NCA had to carry on processing the request for access 
for scientific research purposes, taking into account that the research had no discontinuity. 
Additionally, the research project did not violate the right to a healthy environment and the UNC 
initiated the request for access to genetic resources in 2001. Also, the NCA had to comply with the 
provisions of Decision 391, observing the terms of the procedure provided in the regulations, as 
well as developing standards that would clarify the process, the scope of the concepts of the 
various dependencies and the requirements. 
Another inconsistency of the NCA in this case was evidenced in March 2006, when the 
License Department of the MADS informed the IBUN-UCN that it would proceed to prepare the 
draft of the contract of access for research purposes (Res. 1459 2010), because through Technical 
Concept No. 1652, of 2008, prepared by the Department of Ecosystems, it was noted that the 
project was not viable for industrialization and commercialization. This was a repetition of what 
happened in 2008, when the entity was not conducting commercial activities on the biopolymer. 
After the beginning of the research through Res. 264 of 2008, the Department of Ecosystems 
determined that the project was on its research a development stage, which is why a period of time 
was required before the project could be deemed to be a commercial exploit, (Res. 1459 of 2010). 
Nowadays, the NCA has begun to guarantee the necessary technical and institutional capacities 
and it is expected that it will have the staff continuity needed to operate the access regime. 
 
 
10.2 Case of Bioprospecting in the Galapagos National Park, Ecuador 
 
During 2003 and 2004, a group of researchers led by J. Craig Venter Ph.D., member of the J. Craig 
Venter Institute (IJCV), conducted the " Global Ocean Sampling Expedition" in the Galapagos National 
Park,  collecting  over  150  seawater  samples,  each  of  200-liter  collected  every  200  miles. 
 34 Biodiversity research in megadiverse countries 
 
In this case, a Memorandum of Understanding (MOU) between the Institute for Biological Energy 
Alternatives (IBEA) and Ecuador, was signed establishing the following scope: "Whereas, IBEA is 
undertaking a global ocean expedition for conducting a scientific research project aimed at studying 
microbial diversity with the objective of classifying the Galapagos Islands microbial diversity in its 
coastal waters and terrestrial communities around them." 
The project is presented as an activity to increase knowledge of the microorganisms that inhabit 
the seas and understand how they function in their natural ecosystem, focusing on the study of the 
effects of humans on the environment and understanding the evolution of life on earth. In the case of 
Ecuador, the signed MOU says "(...) to determine the complex interplay between groups of 
microorganisms that affect environmental processes of regional and global importance, conducting 
sampling from the vessel R.V. Sorcerer II, and applying a genomic approach of total environment (...)" 
(Ministry of Environment of Ecuador and The Institute for Biological Energy Alternatives, 2004). 
With regards to the geographical scope of the research, much of the sampling was carried out in 
international waters not subject to the rules of national ABS, and another was executed in the territory 
of 17 countries from different continents and regions: Latin America (Ecuador, Mexico, Panama and 
Honduras); North America (Canada and USA); Oceania; South Pacific (New Caledonia, French 
Polynesia and Vanuatu); Africa (Tanzania and Seychelles); Europe and UK (Sea twill and Bermuda). 
In relation to the resources the MOU refers to microbial diversity and microorganisms, without 
specifying amounts or details, which may be partially explained by the fact that these are water samples, 
but a more complete description is required and may be found in the Collection Permit granted by the 
Galapagos National Park. Additionally, the MOU does not mention the real or potential uses of the 
collected resources in detail, it merely mentions –in a general and abstract way – that the samples on 
which the project is based are useful "(...) to determine the complex interplay between groups of 
microorganisms that affect environmental processes of regional and global (...) importance." 
Within this bioprospecting framework, it must be considered that in 2004 there was evidence that 
marine organisms are of academic non-commercial interest but have potential for industrial processes. 
For instance, they may be precursors to extract the useful enzymes for industry as well as for the biofuels 
industry. Indeed, the IBEA received one million dollars (USD) at the beginning and then an additional 
four million, as funding for its global ocean sampling expedition (Potagge 2006). 
In known contractual agreements, particularly in the "Memorandum of Understanding for 
Collaboration in Microbial Biodiversity", the term of the agreement is of two years from the date of 
subscription. This period may be renewed upon mutual agreement by the Parties, expressed a 
minimum of two months prior to its expiration. In addition, if the parties do not develop a joint Project 
Plan in a period of one year from the subscription, the MOU will automatically cease without any 
further obligations. 
In the case of the MOU between Ecuador and IBEA, it was specified that clauses 4, 5 and 8 
would survive termination and even after the completion deadline. The clauses referred to intellectual 
property (4), the publication and dissemination of Information (5) and miscellaneous issues (8). In 
addition, the MOU has no specific provisions devoted to monetary benefits as such, since it includes 
them in the terminology used in the CBD, when talking about obtaining greater "knowledge" of 
biodiversity that is useful for "conservation". These commitments are expressed in a rather general 
and abstract manner.  
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There are no indicators in the fifth clause pertaining to publication and dissemination of the 
information, which states: 
 
“In order to make the information available to the global scientific and public communities, the parties 
specifically agree that the raw genomic data shall be provided only with their express permission. Once 
the data have been analyzed, all the information shall be deposited in public databases and published in 
scientific forums, where it shall be acknowledged that the information obtained is part of the genetic 
patrimony of the state of Ecuador.  
  
The IBEA and the MAE, through the Parque Nacional Galápagos, shall jointly collaborate on one or more 
scientific publications analyzing the genomic data in the manner established in the Project Plans 
approved by the appropriate authority. The parties agree that scientists from other countries, who are 
also collaborating in the global sampling expedition, may be acknowledged as coauthors. The MAE, 
through the Parque Nacional Galápagos, agrees to provide cooperation within the scope of its 
jurisdiction and the applicable legal framework in order to facilitate the objectives of the global sampling 
expedition in the Galapagos Islands.  
  
The parties shall also work, as appropriate, on joint activities to disseminate and communicate 
information about and deriving from the collaboration, not only to the scientific community, but also to 
the public in general, and to educational institutions, particularly those in Ecuador, as long as this 
information is used solely for scientific, not commercial, purposes.” 
 
 
The first results reported from the Sargazo were disseminated in 2004, in the scientific journal 
"Science" and most of the remaining findings were published during 2007 in a series of eight articles in the 
open access journal "PlosBiology", with three of them being classified as research. In the processing of the 
permit for biodiversity research, the Charles Darwin Research Station, academic and scientific research 
institution, recommended the approval of the research as this is of great value for a better understanding 
of the role of marine microorganisms in environmental processes." Additionally, a researcher at the 
University of Guayaquil presented a report, which partially supported the issuance of the research permit, 
because he said that the proposal "would increase the scientific, technological and technical capacity at the 
national level on the way to the conservation of biodiversity and sustainable use of biological resources.” 
Today, it has been confirmed that none of the articles credited an Ecuadorian researcher listed 
as coauthor. In the first research article published in "PlosBiology", out of the 34 co-authors: 28 are 
located in the United States of America; four are residents or are ascribed to Mexican universities; one 
is a resident or is ascribed to research institutions in Costa Rica, and one is linked to an institution in 
Chile. In itself, authorship or co-authorship of an article is not something that can be obtained by way 
of distribution of profits, because it depends on the contribution and effective participation in the 
project or during the writing of the article. However, the absence of Ecuadorian authors suggests that 
the project omitted direct benefits, at least in terms of the research training and the transfer or 
exchange of knowledge or technology. One of the articles contains acknowledgments to staff from 
Ecuador and other countries, while other articles recognize the sovereignty of countries over the 
samples, which can hardly be seen as fair and equitable sharing of benefits arising from the utilization 
of genetic resources. 
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The situation of the MOU should be analyzed carefully, because when the expedition was 
conducted, the Bonn Guidelines of 2002 were already in effect, and though they are not binding, they 
could be considered as a factor in the relationship between the Parties represented by Ecuador and 
IBEA. At present, scientific publications are in the public domain and genetic information obtained is 
in two databases, namely: GenBank, managed by the National Institute of Health in the United States 
of America; and the CAMERA project managed by the University of California, San Diego, and the 
IJCV, which hosts metagenomic information. Regarding patents or other intellectual property rights 
(IPR) over genomic DNA and sequenced data, IJCV indicated that these would not be requested. In 
fact, a preliminary inquiry confirms this. However, there are two patents under obligation to disclose 
federal funding (Bayh Dole Act), which claim the same sponsorship from the Department of Energy of 
the United States of America (DOE) because it co-financed the expedition; with documents proving 
the existence of financial support for two projects: "Global Ocean Sampling Expedition" and 
"Reconstruction of a Bacterial Genome from DNA Cassettes”. 
There are two other projects whose research objective has been focused on ecosystems and 
marine environments. Projects Malaspina from Spain and “Tara Oceans" from France, bear some 
similarity to the Sorcerer II of the United States of America. The first, conducted between 2010 and 
2011, gathered at least 250 researchers, had an investment of 17 million Euros, reported 300 sampling 
stations, included 21 institutions from different countries, indirectly linked 35 countries in research, 
and collected 70,000 samples of water, air and plankton (www. expedicionmalaspina.es). The second, 
was developed with funding of 9 million Euros, visited 32 countries, registered three sampling permit 
rejections in the national waters of Oman, India and Ecuador (Galapagos Islands), and collected 27,882 
samples from 153 sampling stations (http://oceans.taraexpeditions.org/en/). The three projects derive 
some inspiration from both, the endeavor of Charles Darwin on the Beagle, and on the HMS 
Challenger. According to some analysts, the analogy is used as a marketing or self-promoting tool, or 
as an instrumental strategy because it serves as a defense against possible accusations under the 
premise: "If it’s in the Darwin school of Biopiracy, then fine" (Nicholls 2007: 383). 
When contrasting the statements of J. Craig Venter on the alleged non-profit nature of the 
expedition with those of the Director of the DOE, and referring to the motivations for financing the 
project, Matthew Rimmer (2009), professor at the National University of Australia, suggests that the 
investment of the DOE assumes that the Sorcerer II Expedition was intended to be more than an 
exercise in basic science. The scientist states that: "The Institute sought to explore energy solutions for 
environmental problems such as global warming and find new biological sources of cleaner and more 
efficient fuels, including hydrogen. As such, there was an underlying motivation when carrying out 
research on microorganisms with the prospect of achieving commercially useful results" (Rimmer 
2009). 
A final aspect to highlight is the intervention of international diplomacy, since this case was 
presented in the media as scientific research, with the J. Craig Venter team mentioning that it had 
support from the DOE to get research and collection permits in the countries where samples were 
obtained: "In accordance with national laws and international treaties, and under the guidance of the 
State Department of the United States of America, IBEA obtains permits for research and sampling 
from each country in which samples will be collected "(Rimmer 2009). The oceanic expedition was no 
stranger to controversy, such as the one arising when the French government opposed sampling in 
their Polynesia. However, the authorization was granted when the government of United States of 
America moved its political influences (Rimmer 2009). 
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The analysis of the case studies mentioned above proves or at least suggests that –in addition to 
being technical and legal issues– scientific research, access and benefit sharing are also permeated by 
power relations as well as by media and political influence. In contrast, the French expedition "Tara 
Oceans" that years later tried to sample in the Galapagos Islands as part of a global marine research 
project, gave up and argued that it was more than a year of negotiations with no response to its 
request for permission research. So, one reason is perhaps a weaker political influence of the French 
government in these matters; and the other might be that as a result of the experience of the Sorcerer 
II expedition, the process of collection permits for foreigners has become stricter in Ecuador. 
 
 
11. Final Considerations 
 
This analysis argues that the characterization of diverse countries as suppliers and the operative 
capacity of access regimes are considered as unexpected effects against the strengthening of 
endogenous scientific and technological capacities. The negotiations under the framework of the 
CBD, identifying countries of origin of resources as suppliers only downplays the processes that enable 
the gradual formation of scientific and technological capabilities. It also belittles the generation of 
knowledge and diverse varieties of biodiversity that enrich agriculture and food as a result of the 
innovations and practices of indigenous peoples and local communities. Meanwhile, access regimes 
designed with the expectation of partaking in the economic benefits derived from the use of genetic 
resources also have an unexpected consequence: making genetic research conducted by national 
researchers illegal due to imposing parameters designed for industrial and international 
bioprospectors. 
The possible solutions examined should facilitate access to research on biological and genetic 
diversity, while recognizing the rights of countries of origin and ensuring the benefit sharing arising 
from their use. For this reason, emphasis is placed on applying an approach that guarantees the 
conduction of research with facilitated access through framework agreements, as one of the options, 
while recognizing the potential to identify genetic material and byproducts of industrial and 
technological application. 
Some measures which can be pointed out in the management of access regimes and which 
safeguard the objectives of the CBD, become a temporary option that may provide flexibility given the 
current situation and strengthen national research. For instance, research projects financed with state 
resources should start and advance while applications are being processed. Likewise, when an 
agreement regarding benefit sharing is established in advance at the time access to genetic resources 
for commercial purposes is granted, options should be designed so as not to restrict the use of the 
material and research results for public purposes or developments that generate benefits for the 
country. Particularly when a research process in biological and genetic diversity is embedded in value chains 
and innovation sequences, a facilitated access approach must recognize the continuity between research, 
innovation and development. Also, its mechanisms must encourage researchers to report any possible 
commercial potential for the implementation of projects. 
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Some points raised by previous studies on access in the region are confirmed in this analysis, 
suggesting the importance of flexible treatment for scientific purposes in the context of a 
comprehensive ABS regulatory system. Thus, user countries can establish measures regarding a 
possible commercial use of genetic resources, allowing the country of origin to know if such use 
existed in order to exercise their rights in foreign jurisdiction in case there is a breach of the 
established conditions (López Cabrera Medaglia and Silva 2008). 
The experiences of the region, such as the case of Colombia suggest that access regime designs 
and their regulations must prioritize the strengthening of the endogenous scientific and technological 
capacities without expecting any monetary benefit from the industrial application of genetic 
resources. In this regard, the experience of Costa Rica should be considered given the fact that the 
National Biodiversity Institute (INBio) prioritizes the improvement of their scientific and technological 
capabilities as well as programs for conservation and sustainable use of biodiversity. 
National research programs involving research institutions and universities which are the 
beneficiaries of an access framework agreement, become a technology platform for access to genetic 
resources, research groups and training in advanced technology in the countries of origin. They also 
contribute in the exercise of their rights to biodiversity. With this perspective, a broad spectrum of 
possibilities for international cooperation emerge when attracting research centers and universities with 
the largest scientific progress in different scientific areas. Cases of countries that have progressed in terms 
of their endogenous capacities, such as Brazil, Costa Rica and Cuba, may be seen as experiences and 
alternatives to promote collaborative programs that facilitate access to biodiversity. 
In terms of political decision, access regimes and their regulations should include appropriate 
provisions to recognize the value and relevance of the collections of organisms, tissues and genetic 
material. Similarly, national DNA banks should be established as they are strategic and work as 
reservoirs for research on biological and genetic diversity. The evaluation of this objective is of  the 
utmost importance when including clauses into access contracts pertaining to sample destruction 
once the research project is concluded. 
Another situation concerning researchers from countries poor in biodiversity and those 
found in the countries of origin of genetic resources, can be evidenced in the emphasis placed on 
requesting differential treatment for research; but at the same time, there are models that show 
efforts to strengthen local capacities. In addition, it is pertinent to refer to political decisions 
regarding schemes for the dissemination of results which are promoted from the perspective of 
scientific interest, but there is not a single model as of yet. Dissemination schemes of genetic data 
based on open and free criteria, do not prevent biopiracy situations per se. Although making the 
information available and including it in the technical status may reduce or prevent the possibility 
of obtaining patents, access to this information is public and anyone who gains access to it may file 
for a patent if it modifies, transforms or combines the information. 
The availability of public information in some cases allows the establishment of business 
models, combining intellectual property rights and services based on databases repositories of free 
access. When  deciding  on access  regulations  or  contracts pertaining to models of dissemination of  
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results, the standardization and adoption of a single model as the most appropriate should be 
avoided. In practice, everyone has potential and limits, advantages and disadvantages and, therefore, 
a case-by-case analysis is required using intellectual property criteria and articulating models of 
dissemination of results with various business schemes. A final point concerns patent applications 
which in themselves do not imply Biopiracy, because they could be validating truly innovative 
products and procedures developed from genetic resources and/or products, meeting the 
requirements of PIC and MAT. 
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